A controlled trial of immunotherapy for asthma in allergic children

N Franklin Adkinson, Peyton A. Eggleston, Donald Eney, Eugene O. Goldstein, Kenneth C Schuberth, John R. Bacon, Robert G Hamilton, Michael E. Weiss, Hasan Arshad, Curtis L Meinert, James A Tonascia, Barbara Wheeler

Research output: Contribution to journalArticle

Abstract

Background: Injections of allergens are widely prescribed for patients with asthma, but little is known about the effectiveness of immunotherapy. Methods: We conducted a double-blind, placebo controlled trial of multiple- allergen immunotherapy in 121 allergic children with moderate-to-severe, perennial (year-round) asthma. The children, who required daily medication for their asthma, were randomly assigned to receive subcutaneous injections of either a mixture of up to seven aeroallergen extracts or a placebo. Maintenance injections were continued for 18 months or longer. Medications were adjusted every two to three weeks on the basis of peak flow rates and symptoms. The principal outcome was the daily medication score. Bronchial sensitivity to methacholine (the concentration provoking a 20 percent decrease in the forced expiratory volume in one second [PC20]) was measured twice yearly. Results: The median medication score declined from 5.4 to 4.9 in the immunotherapy group (P0.6). The number of days on which oral corticosteroids were used was similar in the two groups. Partial or complete remission of asthma occurred in 31 percent of the immunotherapy group and in 28 percent of the placebo group (P>0.5). There was no difference between the groups in the use of medical care, symptoms, or peak flow rates. The median PC20 increased significantly in both groups, but again with no difference between the two groups. Conclusions: Immunotherapy with injections of allergens for over two years was of no discernible benefit in allergic children with perennial asthma who were receiving appropriate medical treatment.

Original languageEnglish (US)
Pages (from-to)324-331
Number of pages8
JournalNew England Journal of Medicine
Volume336
Issue number5
DOIs
StatePublished - Jan 30 1997

Fingerprint

Immunotherapy
Asthma
Placebos
Allergens
Injections
Immunologic Desensitization
Methacholine Chloride
Forced Expiratory Volume
Subcutaneous Injections
Adrenal Cortex Hormones
Maintenance
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A controlled trial of immunotherapy for asthma in allergic children. / Adkinson, N Franklin; Eggleston, Peyton A.; Eney, Donald; Goldstein, Eugene O.; Schuberth, Kenneth C; Bacon, John R.; Hamilton, Robert G; Weiss, Michael E.; Arshad, Hasan; Meinert, Curtis L; Tonascia, James A; Wheeler, Barbara.

In: New England Journal of Medicine, Vol. 336, No. 5, 30.01.1997, p. 324-331.

Research output: Contribution to journalArticle

Adkinson, N Franklin ; Eggleston, Peyton A. ; Eney, Donald ; Goldstein, Eugene O. ; Schuberth, Kenneth C ; Bacon, John R. ; Hamilton, Robert G ; Weiss, Michael E. ; Arshad, Hasan ; Meinert, Curtis L ; Tonascia, James A ; Wheeler, Barbara. / A controlled trial of immunotherapy for asthma in allergic children. In: New England Journal of Medicine. 1997 ; Vol. 336, No. 5. pp. 324-331.
@article{f69b17e433814d94b6e7006a0693a148,
title = "A controlled trial of immunotherapy for asthma in allergic children",
abstract = "Background: Injections of allergens are widely prescribed for patients with asthma, but little is known about the effectiveness of immunotherapy. Methods: We conducted a double-blind, placebo controlled trial of multiple- allergen immunotherapy in 121 allergic children with moderate-to-severe, perennial (year-round) asthma. The children, who required daily medication for their asthma, were randomly assigned to receive subcutaneous injections of either a mixture of up to seven aeroallergen extracts or a placebo. Maintenance injections were continued for 18 months or longer. Medications were adjusted every two to three weeks on the basis of peak flow rates and symptoms. The principal outcome was the daily medication score. Bronchial sensitivity to methacholine (the concentration provoking a 20 percent decrease in the forced expiratory volume in one second [PC20]) was measured twice yearly. Results: The median medication score declined from 5.4 to 4.9 in the immunotherapy group (P0.6). The number of days on which oral corticosteroids were used was similar in the two groups. Partial or complete remission of asthma occurred in 31 percent of the immunotherapy group and in 28 percent of the placebo group (P>0.5). There was no difference between the groups in the use of medical care, symptoms, or peak flow rates. The median PC20 increased significantly in both groups, but again with no difference between the two groups. Conclusions: Immunotherapy with injections of allergens for over two years was of no discernible benefit in allergic children with perennial asthma who were receiving appropriate medical treatment.",
author = "Adkinson, {N Franklin} and Eggleston, {Peyton A.} and Donald Eney and Goldstein, {Eugene O.} and Schuberth, {Kenneth C} and Bacon, {John R.} and Hamilton, {Robert G} and Weiss, {Michael E.} and Hasan Arshad and Meinert, {Curtis L} and Tonascia, {James A} and Barbara Wheeler",
year = "1997",
month = "1",
day = "30",
doi = "10.1056/NEJM199701303360502",
language = "English (US)",
volume = "336",
pages = "324--331",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "5",

}

TY - JOUR

T1 - A controlled trial of immunotherapy for asthma in allergic children

AU - Adkinson, N Franklin

AU - Eggleston, Peyton A.

AU - Eney, Donald

AU - Goldstein, Eugene O.

AU - Schuberth, Kenneth C

AU - Bacon, John R.

AU - Hamilton, Robert G

AU - Weiss, Michael E.

AU - Arshad, Hasan

AU - Meinert, Curtis L

AU - Tonascia, James A

AU - Wheeler, Barbara

PY - 1997/1/30

Y1 - 1997/1/30

N2 - Background: Injections of allergens are widely prescribed for patients with asthma, but little is known about the effectiveness of immunotherapy. Methods: We conducted a double-blind, placebo controlled trial of multiple- allergen immunotherapy in 121 allergic children with moderate-to-severe, perennial (year-round) asthma. The children, who required daily medication for their asthma, were randomly assigned to receive subcutaneous injections of either a mixture of up to seven aeroallergen extracts or a placebo. Maintenance injections were continued for 18 months or longer. Medications were adjusted every two to three weeks on the basis of peak flow rates and symptoms. The principal outcome was the daily medication score. Bronchial sensitivity to methacholine (the concentration provoking a 20 percent decrease in the forced expiratory volume in one second [PC20]) was measured twice yearly. Results: The median medication score declined from 5.4 to 4.9 in the immunotherapy group (P0.6). The number of days on which oral corticosteroids were used was similar in the two groups. Partial or complete remission of asthma occurred in 31 percent of the immunotherapy group and in 28 percent of the placebo group (P>0.5). There was no difference between the groups in the use of medical care, symptoms, or peak flow rates. The median PC20 increased significantly in both groups, but again with no difference between the two groups. Conclusions: Immunotherapy with injections of allergens for over two years was of no discernible benefit in allergic children with perennial asthma who were receiving appropriate medical treatment.

AB - Background: Injections of allergens are widely prescribed for patients with asthma, but little is known about the effectiveness of immunotherapy. Methods: We conducted a double-blind, placebo controlled trial of multiple- allergen immunotherapy in 121 allergic children with moderate-to-severe, perennial (year-round) asthma. The children, who required daily medication for their asthma, were randomly assigned to receive subcutaneous injections of either a mixture of up to seven aeroallergen extracts or a placebo. Maintenance injections were continued for 18 months or longer. Medications were adjusted every two to three weeks on the basis of peak flow rates and symptoms. The principal outcome was the daily medication score. Bronchial sensitivity to methacholine (the concentration provoking a 20 percent decrease in the forced expiratory volume in one second [PC20]) was measured twice yearly. Results: The median medication score declined from 5.4 to 4.9 in the immunotherapy group (P0.6). The number of days on which oral corticosteroids were used was similar in the two groups. Partial or complete remission of asthma occurred in 31 percent of the immunotherapy group and in 28 percent of the placebo group (P>0.5). There was no difference between the groups in the use of medical care, symptoms, or peak flow rates. The median PC20 increased significantly in both groups, but again with no difference between the two groups. Conclusions: Immunotherapy with injections of allergens for over two years was of no discernible benefit in allergic children with perennial asthma who were receiving appropriate medical treatment.

UR - http://www.scopus.com/inward/record.url?scp=0348013017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348013017&partnerID=8YFLogxK

U2 - 10.1056/NEJM199701303360502

DO - 10.1056/NEJM199701303360502

M3 - Article

C2 - 9011784

AN - SCOPUS:0348013017

VL - 336

SP - 324

EP - 331

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 5

ER -